• DRAMP ID

    • DRAMP18086
    • Name

    • Telavancin(TD-6424)
    • Sequence

    • Not available
    • Description

    • Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria.
    • Activity

    • Antibacterial
    • Target Organism

      • No MICs found on DRAMP database
    • Reference

      • New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.(PMID: 20426497)
    • Medical use

    • Osteomyelitis, Bacterial infections (I)
    • Company

    • Clinigen Group plc/Innoviva Inc./Pendopharm/Theravance Biopharma Inc./University of Illinois
    • Stage of Development

    • In market
    • Comments

    • Telavancin prevents polymerization of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) and cross-linking of peptidoglycan by binding to D-Ala-D-Ala. As a result, inhibition of bacterial cell wall synthesis occurs. Furthermore, telavancin disrupts membrane potential and cell permeability as a result of the lipophillic side chain moiety. This additional bactericidal mechanism is what sets telavancin apart from vancomycin.